SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 58.08+0.9%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: rkrw who wrote (20649)7/31/2006 2:02:54 PM
From: dr.praveen  Read Replies (1) of 52153
 
Predix inks potential $300M deal with Amgen
Monday July 31, 11:35 am ET

Predix Pharmaceuticals Inc. has inked a development deal with biotechnology giant Amgen Inc. worth more than $300 million assuming certain milestones are met.

The Lexington, Mass., company announced on Monday that it had agreed to an exclusive collaboration and licensing deal with California-based Amgen (Nasdaq: AMGN - News).

Under terms of the agreement, both companies will to develop existing preclinical and new Predix compounds. Amgen will cover clinical development and commercialization costs, and the company pays $20 million up front. Predix can receive up to $287.5 million in additional payments if the drugs under development meet certain clinical, regulatory and sales milestones.

In addition, Predix can earn royalties on future sales of products resulting from the collaboration.

Predix has four drug candidates in clinical trials focused on anxiety disorder, Alzheimer's disease, pulmonary hypertension and obesity. Five other compounds are in preclinical development.

Predix and Cambridge, Mass.-based Epix Pharmaceuticals Inc. (Nasdaq: EPIX - News) are expected to complete a $90 million merger deal by the end of this summer. Epix shareholders are scheduled to vote Aug. 15 on the merger. The company is expected to keep the Epix name.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext